December 2016

In This Issue

WIPO Re:Search Statistics
Partnership Hub Central
Funding Announcement
Highlighted Contributions
Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

Happy New Year! It may only be January, but 2017 is shaping up to be an impactful year. BVGH’s coordination of a second round of developing country scientist training sabbaticals is well under way. Prospective hosts and visiting scientists have been identified and project and training discussions have commenced. These sabbaticals are being supported by IP Australia through Funds in Trust (FIT) provided to WIPO.

BVGH and WIPO have begun incorporating the feedback obtained from Members and the Advisory Committee into the Five-Year Medium Term Strategic Plan (MTSP) for WIPO Re:Search. The MTSP will be published and presented publicly at the WIPO Re:Search five-year anniversary meeting, which will be held concurrent to the 70th World Health Assembly. Stay tuned for more information about the MTSP and anniversary meeting.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

Special Announcement

Have you presented or published the results of your WIPO Re:Search collaboration? If so, please let Katy know so that we can feature your work in the next Snapshot as well as on our website.
WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

---

Expected Product

<table>
<thead>
<tr>
<th>Expected Product</th>
<th>Drug</th>
<th>Vaccine</th>
<th>Diagnostic</th>
<th>Basic Research</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>8</td>
</tr>
</tbody>
</table>

IP Asset Shared

<table>
<thead>
<tr>
<th>IP Asset Shared</th>
<th>Data/Reagent</th>
<th>Expertise/Advice</th>
<th>Samples</th>
<th>Technology/Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Current Pipeline Stage

<table>
<thead>
<tr>
<th>Current Pipeline Stage</th>
<th>Basic Research/Discovery</th>
<th>Screening for Repurposing</th>
<th>Hit to Lead</th>
<th>Preclinical Development</th>
<th>Clinical Development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

Participating WIPO Re:Search Members:

California Institute of Technology  Novartis
Centre Pasteur du Cameroun          Pfizer
Emory University                    Stanford University
Institut Pasteur de Tunis           University of Kansas
McMaster University                 Walter Reed Army Institute of Research
National Institutes of Health
The following are BVGH's WIPO Re:Search objectives and deliverables for 2017:

**Agreements:**
1. Establish 8 new “targeted” agreements
2. Provide alliance management support to ongoing collaborations

**Recruiting:**
1. Recruit 3-6 new targeted User Members*
   *Targeted User Members include those from select countries and regions - Australia, Indo-Pacific, and East Africa

**Communications:**
1. Continue activities to increase awareness of WIPO Re:Search:
   - Monthly Snapshot newsletter
   - 2017 Mid-Year and Annual Report
   - Increase social media presence (Twitter, LinkedIn, etc.)
   - Present WIPO Re:Search at two key conferences and raise awareness of WIPO Re:Search at three key events
2. Develop the WIPO Re:Search five-year Medium Term Strategic Plan

**Sabbaticals**
1. Manage WIPO Re:Search developing country researcher training sabbaticals through IP Australia's Funds in Trust (FIT) 2

---

**BVGH FundFinder Featured Funding Announcement**

**International Short Visits**
The International Short Visits scheme is aimed at researchers in Switzerland who wish to go abroad for a short period or researchers abroad who wish to collaborate with researchers in Switzerland. During the visit, they pursue a small joint research project.

Short visits may last from one week to three months. There are no geographical and topical restrictions.

**Funding amount:** Depends on destination; grant includes travel, room, and board expenses.

**Funder:** Swiss National Science Foundation

**Deadline:** Applications accepted on a rolling basis

**Eligibility:** Applicant must hold a doctorate (or comparable) degree

For more information about BVGH FundFinder, please email Katy Graef.

---

**Highlighted Contributions**

Do you have an asset that you are willing to contribute to another WIPO Re:Search Member to further neglected tropical disease, malaria, or tuberculosis research and development? Email Ujwal Sheth to learn how you can have your asset summarized in the WIPO Re:Search Database and featured in an upcoming Snapshot newsletter.
## Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar. 12-17</td>
<td>Gordon Research Conference: Advances in Basic and Translational Research in Tropical Infectious Diseases</td>
<td>Galveston, Texas</td>
<td>Website</td>
</tr>
<tr>
<td>Mar. 31</td>
<td>9th Annual Center for Emerging &amp; Neglected Diseases (CEND) Symposium</td>
<td>Berkeley, California</td>
<td>Website</td>
</tr>
<tr>
<td>April 22-25</td>
<td>27th European Congress of Clinical Microbiology and Infectious Diseases</td>
<td>Vienna, Austria</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada

---

*Copyright © 2017 BVGH, All rights reserved.*

*Our mailing address is:*
401 Terry Avenue N., Seattle, WA 98109

unsubscribe from this list  update subscription preferences
Dear WIPO Re:Search Members and Friends,

The global health landscape continues to evolve. Progress has been made in tackling some infectious diseases, yet others are still having a devastating toll on families, communities, and low- and middle-income country economies. BVGH closely monitors the changing disease landscapes and product pipelines, and going forward, we will focus our WIPO Re:Search partnering activities on establishing collaborative research and development (R&D) projects that address the most pressing neglected infectious disease needs.

In April 2017, to mark the fifth anniversaries of the World Health Organization (WHO) Neglected Tropical Disease (NTD) Roadmap and the London Declaration on NTDs, the WHO will host the Second Global Partners’ Meeting on NTDs and Uniting to Combat NTDs will host the NTD Summit. Both events will convene key global health players to discuss progress made, future perspectives, and actions required to meet the Sustainable Development Goals (SDG) target (3.3) of ending the NTD epidemics by 2030. BVGH closely monitors the changing disease landscapes and product pipelines, and going forward, we will focus our WIPO Re:Search partnering activities on establishing collaborative research and development (R&D) projects that address the most pressing neglected infectious disease needs.

In April 2017, to mark the fifth anniversaries of the World Health Organization (WHO) Neglected Tropical Disease (NTD) Roadmap and the London Declaration on NTDs, the WHO will host the Second Global Partners’ Meeting on NTDs and Uniting to Combat NTDs will host the NTD Summit. Both events will convene key global health players to discuss progress made, future perspectives, and actions required to meet the Sustainable Development Goals (SDG) target (3.3) of ending the NTD epidemics by 2030. BVGH plans to attend these events to learn about and subsequently align our partnering to these important partners and strategies. By shaping our interactions with Members to fit these global initiatives, BVGH will ensure that WIPO Re:Search is filling R&D gaps, meeting the most urgent needs, and having the greatest impact.

The 2016 WIPO Re:Search Partnership Hub Annual Report is now available. Click here to download a copy. If you would like a hard...
copy of the report, please reach out to Erica Jones and we will send one or more copies to you in the mail.

I am pleased to welcome our three newest Members, the Brazilian Biosciences National Laboratory (LNBio), the Eijkman Institute for Molecular Biology, and Monash University.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Alnylam will design and synthesize optimized siRNAs for Dr. Floriano Paes Silva, Laboratory of Experimental and Computational Biochemistry of Drugs, Fiocruz, to conduct gene validation studies via RNAi in his drug discovery efforts against Schistosoma mansoni.

The Center for Infectious Disease Research (CIDR) and the Seattle Structural Genomics Center for Infectious Disease (SSGCID) have agreed to attempt to solve the structure of the Schistosoma mansoni 3-hydroxy-3-methylglutaryl coenzyme A reductase (SmHMGR) for Dr. Conor Caffrey, Nematode and Trematode Core Director, Center for Discovery and Innovation in Parasitic Diseases, University of California, San Diego (UCSD). Dr. Caffrey has been exploring the druggability of SmHMGR using HMG CoA reductase inhibitors (statins) provided by MSD, known as Merck & Co., Inc. in the United States and Canada.

New Member Announcement

We are pleased to announce that the Brazilian Biosciences National Laboratory (LNBio), Eijkman Institute for Molecular Biology, and Monash University have joined WIPO Re:Search.

Founded in 2009, the Brazilian Biosciences National Laboratory (LNBio) is dedicated to cutting-edge biotechnology, healthcare, and life sciences research and development. Along with its other programmatic areas, LNBio scientists focus on understanding the molecular mechanisms of pathogenicity and virulence, drug development for parasitic and bacterial diseases, and host-pathogen interactions.

The Eijkman Institute for Molecular Biology located in Jakarta, Indonesia, is focused on advancing basic and applied research into biomedicine, biodiversity, biotechnology, and biosecurity. The Institute’s infectious disease research program focuses on dengue and malaria including mechanisms of antimalarial resistance, antimalarial natural products drug discovery, malaria vaccine development, host response to dengue virus infection, and dengue vaccine clinical trials.
Monash University was established in Melbourne, Australia in 1958 as a tertiary education institution focused on science and technology research. University faculty members study an array of diseases including malaria, Chagas disease, and tuberculosis. Its Faculty of Pharmacy and Pharmaceutical Sciences has expertise and infrastructure to support drug candidate optimization, drug delivery, and medicinal chemistry.

---

**Partnership Hub Central**

On February 3rd, WIPO organized the “WIPO Re:Search and Global Health Lunch Briefing for Ambassadors”, co-hosted by WIPO Assistant Director-General Minelik Getahun and Egyptian Ambassador Amr Ramadan, featuring a special guest, Dr. John Reeder, Director of the WHO-hosted Special Programme for Research and Training in Tropical Diseases (TDR). The objective of the lunch was to update representatives from over 20 countries on WIPO Re:Search activities, encourage support for the Consortium’s activities around the 2017 World Health Assembly, and inform them of the second round of WIPO Re:Search training sabbaticals focused on the Asia-Pacific region.

From left to right: John Reeder, Director, TDR; Ambassador Amr Ramadan (Egypt); WIPO Assistant Director-General Minelik Getahun; Edward Kwakwa, Director, Dept. of Global Challenges and Traditional Knowledge, WIPO; and Ambassador Sabrina Dallafior Matter (Switzerland)

---

**BVGH FundFinder Featured Funding Announcement**

**E-Asia Joint Research Program (JRP)**

The e-ASIA Joint Research Program aims to develop a vibrant and collaborative research community in science and technology, to promote innovation in the Eastern Asian region, and to contribute to the region’s economic developments. Through multilateral collaboration for medical research and development in the field of health research, the aim of the joint call is not only to contribute to development of regional science, but also to overcome public and medical problems in East Asia in the near future. The e-Asia JRP invites research proposals focusing on infectious diseases and cancer research. Multilateral collaborations must involve scientists from at least three of the following countries: Cambodia, Japan, New Zealand, the Philippines, Russia, the USA, and Vietnam. Funding provided is intended to enhance capacity of the applicants to collaborate, however funding may also cover some of the local research costs that are necessary for the collaboration.
**Funding amount:** Not specified  
**Funder:** Co-funded by the Cambodian Ministry of Health, Japan Agency for Medical Research and Development, New Zealand Health Research Council, Philippine Department of Science and Technology, Russian Foundation for Basic Research, NCI/NIH, NIAID/NIH, and Vietnam Ministry of Science and Technology  
**Deadline:** February 28, 2017  
**Eligibility:** Scientists based in Cambodia, Japan, New Zealand, the Philippines, Russia, the USA, and Vietnam are eligible to apply.

For more information about BVGH FundFinder, please email Cathy Manner.

---

**Member Spotlight**

The **Medicines for Malaria Venture** (MMV) **15th Call for Proposals** is now open. This year MMV is currently welcoming research proposals in three areas:

**Novel families of molecules in the hit-to-lead or lead optimization stages without G6PD deficiency liabilities that either:** kill or reactivate hypnozoites for use as part of a *P. vivax* radical cure or have activity against sexual stage V gametocytes and evidence of transmission blocking in a standard membrane feeding assay.

**Novel chemical series with EC50 <500nM and that have one or more of the following key features:** a known, novel mechanism of action; an inability to select resistant mutants *in vitro*; activity at more than one lifecycle stage; or a long half-life and confirmed *in vivo* efficacy.

**Novel approaches for screening**

Applications are due by March 24, 2017.

---

**Highlighted Contributions**

Featured this month are two contributions submitted by the **Walter Reed Army Institute of Research** (WRAIR) to the [WIPO Re:Search Database](https://www.wipo.int/research/en/).

**The Chemical Information System (CIS) (ID: 2162)**  
The Chemical Information System (CIS) is a research and management tool developed by the Department of Chemical Information. CIS use and function has evolved from a relatively simple inventory system to a powerful, integrated, cheminformatics research and management tool.

The Suite for Automated Global Electronic bioSurveillance (SAGES) is a collection of modular, flexible, freely-available software tools for electronic disease surveillance in resource-limited settings. One or more SAGES tools may be used in concert with existing surveillance applications or the SAGES tools may be used en masse for an end-to-end biosurveillance capability. This flexibility allows for the development of an inexpensive, customized, and sustainable disease surveillance system. The ability to rapidly assess anomalous disease activity may lead to more efficient use of limited resources and better compliance with
WIPO Re:Search In the News

The International Society for Neglected Tropical Diseases (ISNTD) is celebrating global advocacy initiatives and five years of the London Declaration on NTDs during its ISNTD Festival 2017. The ISNTD Festival 2017 aims to bring creative industries together for global health and change. As part of its program, the Festival will be showcasing various mass media campaigns, films, and photos focused on raising awareness of NTDs. The WIPO Re:Search video describing former WIPO Re:Search sabbatical participant Dr. Fidelis Cho-Ngwa’s research sabbatical at Novartis and his onchocerciasis drug discovery will be showcased at the Festival.

The Festival will be held on February 23, 2017 at the Barbican Centre, London, UK. More information is available on the event [website](#).

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 21</td>
<td>ISNTD Bites: vector control solutions for NTDs and global health</td>
<td>London, UK</td>
<td>Website</td>
</tr>
<tr>
<td>April 19-22</td>
<td>Uniting to Combat NTDs: Neglected Tropical Diseases Summit</td>
<td>Geneva, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>April 22-25</td>
<td>27th European Congress of Clinical Microbiology and Infectious Diseases</td>
<td>Vienna, Austria</td>
<td>Website</td>
</tr>
</tbody>
</table>
*Known as EMD in the US and Canada | **Known as Merck in the US and Canada
Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

Beyond the partnering and alliance management activities that are central to our WIPO Re:Search responsibilities, the BVGH team has been busy planning research training sabbaticals. Last year WIPO Re:Search received additional funding, through IP Australia’s Funds in Trust (FIT) to WIPO, to develop sabbatical exchanges for Asian-Pacific researchers at Australian research institutes. BVGH and WIPO subsequently met with Australian researchers and the Australian Department of Foreign Affairs and Trade (DFAT) to agree on plans for the WIPO Re:Search sabbatical program. Since that initial meeting, BVGH has engaged potential participants, matched participants to host organizations, and framed plans for the research and training to be undertaken through these sabbaticals. I am pleased to report that we have made good progress; BVGH has confirmed the participation of host labs and matched them with their research fellows. The specific training programs and research projects for each fellow are being finalized and the first sabbaticals are scheduled to begin in mid-2017. If you would like to learn more about the WIPO Re:Search training sabbatical program, please email Ujwal Sheth.

I am pleased to welcome our two newest Members, James Cook University and Makerere University.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Special Announcement

The 2016 WIPO Re:Search Partnership Hub Annual Report is now available. Click here to download a copy. If you would like a hard copy of the report, please reach out to Erica Jones and we will send one or more copies to you in the mail.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

Cornerstones of Collaboration

The National Institute of Parasitic Diseases, China CDC (NIPD) will sequence the K13 gene of Plasmodium falciparum parasites found within malaria patient blood samples obtained by the Centre Pasteur du Cameroun (CPC). The researchers seek to assess the development of artemisinin resistance in Plasmodium parasites circulating in Cameroon, and to compare parasite genotypes with the patients’ responses to treatment – specifically the rate of parasite clearance.
**New Member Announcement**

We are pleased to announce that **James Cook University** and **Makerere University** have joined WIPO Re:Search.

A leading institution focused on the tropics, **James Cook University** in Australia conducts internationally-recognized research in marine sciences, biodiversity, and tropical ecology and medicine. Researchers at its Australian Institute of Tropical Health & Medicine focus on host-pathogen interactions of Plasmodium and Mycobacterium tuberculosis, helminth vaccinology, vector-based approaches to dengue fever control, anti-parasitic discovery, and more.

**Makerere University**, located in Kampala, Uganda, is one of Africa’s oldest universities. Researchers at the university are focused on the molecular biology and clinical pharmacology of malaria. The Infectious Disease Institute at the College of Health Sciences performs an array of research projects including those focused on HIV/AIDS and clinical assessment of tuberculosis diagnostics.

**Partnership Hub Central**

Tom Bombelles (WIPO) presented an overview of IP and global health issues, including WIPO Re:Search, to the United Nations Human Rights Council (HRC) in Geneva, Switzerland. The HRC convened a historic session on innovation, IP, and global health issues, within the context of the 2016 UN Secretary General's High-Level Panel report on access to medicines.
**BVGH FundFinder Featured Funding Announcement**

**International Research in Infectious Diseases, including AIDS**

The purpose of this opportunity is to encourage the submission of applications from institutions in eligible foreign countries to conduct studies in infectious disease research. These grants will serve to build independent research capacity by providing direct funding to investigators who do not currently have NIH-funded grant or contract awards for research projects. The intent of these activities is to advance the development of local scientific expertise. Topics of interest are limited to research on infectious diseases including tuberculosis; malaria; diarrheal, respiratory, and enteric diseases; parasitic diseases; and vector-borne diseases. Studies may be proposed on any aspect of infectious disease research, except clinical trials. Development of basic, immunological, microbiological, biostatistical, epidemiological, data management, and clinical research capacity is encouraged.

Collaborative projects involving investigators and institutions from international sites and the U.S. are particularly encouraged; however, a U.S. partner is not required.

**Funding amount:** $125,000/year for up to five years  
**Funder:** National Institutes of Health (NIH)  
**Deadline:** Letter of intent due April 22, 2017  
**Eligibility:** Applicant’s organization must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank definition).

For more information about BVGH FundFinder, please email Cathy Manner.

---

**Highlighted Contributions**

Featured this month are three contributions submitted by the University of Lagos to the WIPO Re:Search Database.

**Malaria diagnostics quality assurance services (ID: 2721)**
The University of Lagos has the capacity to provide quality assurance services for malaria diagnostics and maintains panels these services.

**Malaria slide bank (ID: 2741)**
The University of Lagos has a bank of malaria microscopy slides. Each slide is characterized by *Plasmodium* species, lifecycle stage, and parasitemia.

**Malaria biobank (ID: 2703)**
The University of Lagos maintains a semi-characterized biobank with detailed informed consent for future use. The biobank consists of malaria parasites characterized by microscopy in dry blood spots, whole blood, plasma, and serum.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.
# Upcoming Global Health Meetings

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 19-22</td>
<td>Neglected Tropical Diseases Summit</td>
<td>Geneva, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>April 26-28</td>
<td>6th International Giardia &amp; Cryptosporidium Conference</td>
<td>Havana, Cuba</td>
<td>Website</td>
</tr>
<tr>
<td>May 16-20</td>
<td>6th World Congress on Leishmaniasis</td>
<td>Toledo, Spain</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada*
April 2017

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

The World Health Organization (WHO) will celebrate the publication of the Fourth WHO Report on Neglected Tropical Diseases this month at the WHO Global Partners Meeting on Neglected Tropical Diseases. It is encouraging to see the strides the world has made in the fight against NTDs. For instance the number of new human African trypanosomiasis cases has decreased 89% since 2000. Only 25 cases of dracunculiasis were detected last year, and yaws has been eliminated in India. Many of our WIPO Re:Search Members have been critical contributors to this important progress.

Still there is a great deal of work that must be done. The suffering of nearly two billion individuals across the world who are infected with a soil-transmitted helminth must be alleviated. The lost productivity resulting from 390 million dengue fever cases occurring each year must be prevented. WIPO Re:Search is a key component of the global movement to make important new product discoveries that will save lives and eliminate the devastation caused by neglected infectious diseases.

Katy Graef will be attending the NTD Summit 2017 hosted by Uniting to Combat NTDs. If you will be attending and would like to meet, please reach out to Katy.

Congratulations to WIPO Re:Search Members, Merck KGaA, Drugs for Neglected Diseases initiative (DNDi), Novartis, and the Liverpool School of Tropical Medicine (LSTM), for receiving awards for their communications efforts at this year’s International Society for NTDs (ISNTD) Festival.

I am pleased to welcome our newest Members, the Institut de Recherche en Sciences de la Santé; Papua New Guinea Institute of Medical Research; and the Structural Genomics Consortium.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
**Special Announcement**

**Save the Date:** WIPO will be hosting the WIPO Re:Search Biennial Member Meeting at its headquarters on Tuesday, May 23, 2017. The WIPO Re:Search Five-Year Strategic Plan will be officially launched during the meeting.

---

**WIPO Re:Search Statistics**

![Agreements and Members](image)

112 Agreements
121 Members

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

**WIPO Re:Search Members in Asia**

- **Bangladesh**
  - International Centre for Diarrhoeal Disease Research, Bangladesh
- **China**
  - National Institute of Parasitic Diseases
  - Guangzhou Institutes of Biomedicine and Health
- **India**
  - National Institute of Immunology
  - Indian Council for Medical Research
  - International Centre for Genetic Engineering and Biotechnology
  - Operation ASHA
- **Indonesia**
  - Eijkman Institute for Molecular Biology
  - Institut Teknologi Bandung
- **Japan**
  - Eisai Co., Ltd.
  - Takeda Pharmaceutical Co., Ltd.
- **Nepal**
  - Center for Molecular Dynamics Nepal
- **Papua New Guinea**
  - Papua New Guinea Institute of Medical Research
- **Philippines**
  - Research Institute for Tropical Medicine
- **Singapore**
  - National University of Singapore
- **South Korea**
  - Institut Pasteur Korea
  - International Vaccine Institute
- **Thailand**
  - National Center for Genetic Engineering and Biotechnology
  - Mahidol University
Cornerstones of Collaboration

**Janssen Research & Development** will provide Professor Andrew Fraser, **University of Toronto** with its Jump-stARter library, a set of 80,000 chemically diverse, high-quality compounds that have been carefully selected to represent chemical diversity. Professor Fraser’s lab will screen the library against *C. elegans* to identify inhibitors of a unique metabolic pathway found in parasitic worms.

New Member Announcement

We are pleased to announce that the **Institut de Recherche en Sciences de la Santé; Papua New Guinea Institute of Medical Research;** and the **Structural Genomics Consortium** have joined WIPO Re:Search.

The **Institut de Recherche en Sciences de la Santé** (IRSS) is one of four institutes of the National Center for Scientific and Technological Research (CNRST) in Burkina Faso. Researchers at IRSS are developing malaria transmission-blocking vaccines, conducting studies on *Plasmodium*-host interactions, and studying how these interactions affect vaccine efficacy. Additional studies of medicinal plants are also ongoing.

The **Papua New Guinea Institute of Medical Research** (PNGIMR) was established in 1968. While headquartered in Goroka, PNGIMR has five branches spread across Papua New Guinea and two additional study sites. The institute’s programs focus on health problems of most importance to the country including malaria, filariasis, and dengue. Specific research interests of PNGIMR include the immune response to malaria during infancy, childhood, and pregnancy; identification of novel *Plasmodium* vaccine antigens; and entomology.

The **Structural Genomics Consortium** (SGC) is a public-private partnership that catalyzes research in human biology and drug discovery by focusing on less well-characterized areas of the human genome. Through its open access policy, the SGC provides its research outputs to the global scientific community. Within its Structural Parasitology division, scientists express, purify, crystalize, and perform chemical screens against parasite proteins. Parasitic diseases of interest include malaria, leishmaniasis, and human African trypanosomiasis.
Partnership Hub Central

Be sure to watch WIPO’s new **WIPO Re:Search video** featuring interviews with Dr. Peter Hotez, WIPO Re:Search Advisory Committee Chair, and President, **Sabin Vaccine Institute**; Dr. Sanaa Botros, Emeritus Professor of Pharmacology, **Theodor Bilharz Research Institute**; Dr. Olaoluwa Pheabian Akinwale, Director of Research (Neglected Tropical Diseases), **Nigerian Institute of Medical Research**; and Dr. Stefan Oschmann, CEO, **Merck KGaA**. Learn how WIPO Re:Search is having a direct impact on the research organizations participating in this global initiative.

---

**BVGH FundFinder Featured Funding Announcement**

**Long-Term Fellowships**

The EMBO Long-Term Fellowships are awarded for a period of up to two years and support post-doctoral research visits to laboratories throughout Europe and the world. International exchange is a key feature in the application process. All fellowships must involve movement between countries.

**Funding amount:** Funding includes a stipend to cover the cost of living in the host country, travel allowance, and other support. Fellowships are awarded for a period of 12-24 months.

**Funder:** EMBO

**Deadline:** No deadlines but there are two annual evaluation dates in February and August

**Eligibility:** Applicants must hold a doctoral degree. Proposed host institute or applicant’s nationality must be from one of the **EMBC Member States**.

For more information about BVGH FundFinder, please email **Cathy Manner**.
Member Spotlight

The Association of University Technology Managers (AUTM) is seeking proposals from those seeking to serve as the host organization for the AUTM Asia 2018 conference. Click here to learn more about AUTM’s request for proposals from host organizations.

Reflecting the current status of the antimalarial pipeline, the changing landscape of malaria – including the emergence of multi-drug resistant malaria in the Greater Mekong sub-region, and the challenges of malaria eradication, Medicines for Malaria Venture (MMV) has published updated antimalarial target candidate profiles (TCPs) and target product profiles (TPPs). The updated TPPs include profiles for the treatment of children or adults and chemoprotection. The TCPs profile molecules to clear asexual parasitemia, with activity against hypnozoites, for chemoprotection, and those with transmission-blocking activities. Click here to read the review.

The Global Health Technologies Coalition (GHTC), Medicines for Malaria Venture (MMV), PATH, and the TB Alliance are hosting a World Health Assembly side event entitled, “Investing in R&D from AMR to Zika: Laying the foundation for sustainable development.” To register for the event, which will take place on Wednesday, May 24th in Geneva, click here.

Highlighted Contributions

Dr. Doudou Sow, Assistant Professor, Department of Parasitology-Mycology, Cheikh Anta Diop University, curates a schistosomiasis sample bank composed of urine samples collected from regions in Senegal with a high prevalence of urinary schistosomiasis. Dr. Sow is willing to explore opportunities to share these samples. Furthermore, Dr. Sow’s laboratory has the capacity to collect additional field samples – including both urine and stool samples from adults and children – upon request by collaborators.

For more information or to discuss potential collaborations regarding this technology, please contact Ujwal Sheth.

Upcoming Global Health Meetings

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Title</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 19-22</td>
<td>Neglected Tropical Diseases Summit</td>
<td>Geneva, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>June 25-30</td>
<td>Gordon Research Conference: New Approaches, New Chemical Entities and New Targets for Tuberculosis Drugs</td>
<td>Barga, Italy</td>
<td>Website</td>
</tr>
<tr>
<td>Sept. 3-8</td>
<td>Molecular and Cellular Biology of Helminth Parasites</td>
<td>Hydra, Greece</td>
<td>Website</td>
</tr>
</tbody>
</table>
*Known as EMD in the US and Canada | **Known as Merck in the US and Canada
Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

Wednesday, April 26th was World Intellectual Property (IP) Day – an annual celebration of the integral role IP plays in encouraging innovation and advancements. While the importance of IP has long been recognized, recent debates – most notably the United Nations High-Level Panel on Access to Medicines – have questioned IP’s role in ensuring access to the innovations it has encouraged. The World Intellectual Property Organization (WIPO) is the UN organization dedicated to promoting a system that uses IP as a means of stimulating innovation and creativity. Its Global Challenges Division is focused on leveraging these innovations to address the world’s greatest challenges including health.

WIPO Re:Search was founded on the belief that IP is not a barrier, rather it is a facilitator to access. This is demonstrated by the number of organizations that have joined WIPO Re:Search as Provider Members – agreeing to abide by the WIPO Re:Search Guiding Principles and to share their IP to advance others’ product development projects for malaria, tuberculosis, and neglected tropical diseases (NTDs). Our company Members have contributed IP in the form of compounds, data, technologies, and more through WIPO Re:Search collaborations.

As we launch the WIPO Re:Search Strategic Plan, 2017-2021, at WIPO’s headquarters in Geneva, BVGH will continue to establish research collaborations revolving around IP sharing. These nascent collaborations will be further evidence of the role and value of IP in both innovation and access.

I am pleased to welcome our newest Members, the Institute of Technology, Bandung; the Institut Pasteur de Madagascar; and the University of Toronto.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Special Announcement

**What:** 2017 WIPO Re:Search Biennial Meeting  
**When:** Tuesday, May 23rd, 9am – 1pm CEST  
**Where:** Room AB 13.1, WIPO Headquarters, Geneva, Switzerland*

WIPO and BVGH encourage all Members to attend the Biennial Meeting. In addition to featuring an overview of WIPO’s and BVGH’s activities and achievements in 2016 and to date, the *WIPO Re:Search Strategic Plan, 2017-2021*, will be formally presented to all Members.

*If you will not be in Geneva, we invite you to join the Biennial Meeting via WebEx. Please contact Maëli Astruc for WebEx login information.

**What:** WIPO and TDR Side Event at the 70th World Health Assembly  
**When:** Thursday, May 25th, 12:15pm – 2pm CEST  
**Where:** Room IX, Palais des Nations, Geneva, Switzerland*

With sponsorship from the Permanent Missions of Egypt, Bangladesh, Indonesia, Namibia, Philippines, Singapore, and Switzerland, WIPO and the Special Programme on Tropical Disease Research (TDR) are hosting a World Health Assembly side event, “Building Capacity for Innovation and Access: Combating Neglected Tropical Diseases”.

* WHA registration is required to attend the side event.

**WIPO Re:Search Statistics**

<table>
<thead>
<tr>
<th>Agreements</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>113</td>
<td>125</td>
</tr>
</tbody>
</table>

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).  

Click [here](#) to view a complete list of WIPO Re:Search Members.
Cornerstones of Collaboration

Janssen Research & Development will provide Dr. Clifton Barry III, Chief, Tuberculosis Research Section, National Institutes of Health (NIH), with its Jump-stARter library. Dr. Barry’s laboratory will screen the Jump-stARter library against Mycobacterium tuberculosis to identify novel scaffolds that inhibit M. tuberculosis growth in vitro under conditions that mimic important aspects of human pathogenesis.
New Member Announcement

We are pleased to announce that the Institute of Technology, Bandung; the Institut Pasteur de Madagascar; and the University of Toronto have joined WIPO Re:Search.

Founded in 1959 by the Indonesian government, the Institute of Technology, Bandung (ITB) is an institution of higher learning in science, technology, and the fine arts. Research conducted at ITB includes studying the effect of combining anti-tuberculosis drugs with medicinal plants to treat multi-drug-resistant *M. tuberculosis* and the molecular epidemiology of *M. tuberculosis* in Indonesia.

Institut Pasteur de Madagascar (IPM) is a member of the Institut Pasteur International Network. IPM’s research interests directly align with Madagascar’s national health priorities, particularly microbiology and epidemiology of infectious diseases. IPM’s research activities include epidemiology of schistosomiasis and soil-transmitted helminthiases, efficacy of traditional medicines against malaria, the immune response to *M. tuberculosis*, and the progression of tuberculosis from a latent to an active infection.

The University of Toronto is Canada’s leading institution of higher learning and one of the world’s top research-intensive universities. Research ongoing at the university includes using *C. elegans* as a model to study parasitic nematode worms; investigating the role of *Leishmania* RNA virus-1 in the pathogenesis of cutaneous leishmaniasis; and developing synthetic surfactants as quinolone sensitizing agents for drug-resistant *Plasmodium*.

Partnership Hub Central

Katy Graef represented WIPO Re:Search at the Second Global Partners’ Meeting on NTDs and the NTD Summit hosted by the World Health Organization (WHO) and Uniting to Combat NTDs, respectively.

BVGH FundFinder Featured Funding Announcement

**Turing Foundation – Leprosy Grant**

The Turing Foundation aims to eliminate the disfiguring disease, leprosy. Leprosy has an incubation period of many years. One of the main challenges in leprosy elimination is to detect the disease in an early stage and to treat it before nerve damages have become irreparable. This is why the Turing Foundation finances scientific research into the early diagnosis and recovery of leprosy.

**Funding amount:** Not specified, however project budgets exceeding €25,000 require an accountant-certified statement upon completion of the project  
**Funder:** Turing Foundation  
**Deadline:** None  
**Eligibility:** Not-for-profit organizations only

For more information about BVGH FundFinder, please email Cathy Manner.
Highlighted Contributions

Do you have an asset that you are willing to contribute to another WIPO Re:Search Member to further neglected tropical disease, malaria, or tuberculosis research and development? Email Ujwal Sheth to learn how you can have your asset summarized in the WIPO Re:Search Database and featured in an upcoming Snapshot newsletter.

WIPO Re:Search in the News

In a recent news release, Merck KGaA, Darmstadt, Germany announced its decision to share a targeted set inhibitors – through WIPO Re:Search – with Dr. Jim McKerrow, Dean, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego (UCSD). Dr. McKerrow will be screening these inhibitors against the parasites that cause Chagas disease, human African trypanosomiasis, and leishmaniasis. Click here to read the news release.

Merck KGaA
Darmstadt, Germany

WIPO Magazine “[…] The best thing we can do to recognize the critical importance of the [IP] system is not to focus on intellectual property (IP) as such, but on the mosaic of results that it enables.” In recognition of World Intellectual Property (IP) Day, Corey Salsberg, Vice President and Global Head of IP Affairs, Novartis, penned an article in WIPO Magazine describing Novartis’ approach to innovation and the relationship between innovation, IP, and improving people’s lives.

Upcoming Global Health Meetings

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 16-17</td>
<td>International Society for Neglected Tropical Diseases (ISNTD) Diagnostics, Drug Discovery &amp; Development (d³)</td>
<td>London, UK</td>
<td>Website</td>
</tr>
<tr>
<td>June 19-22</td>
<td>2017 BIO International Convention</td>
<td>San Diego, California</td>
<td>Website</td>
</tr>
<tr>
<td>Sept. 10-14</td>
<td>Keystone Symposium: Vectors, Pathogens and Diseases: Current Trends and Emerging Challenges</td>
<td>Durban, South Africa</td>
<td>Website</td>
</tr>
</tbody>
</table>
Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

The World Health Organization (WHO) held its 70th World Health Assembly (WHA) in Geneva last month. WIPO and BVGH took advantage of this gathering to bring Members together for the WIPO Re:Search biennial meeting and to launch the WIPO Re:Search Strategic Plan.

In addition to hosting the annual meeting, WIPO led the coordination of a WHA side event to feature WIPO Re:Search capacity building and raise awareness of the impact the Consortium is having across NTDs, malaria, and tuberculosis.

In her last official address as the WHO Director General, Dr. Margaret Chan noted that the successes made by the neglected tropical disease community, which includes industry, demonstrated the relevance of the WHO.

As we say goodbye to Dr. Chan, it is our pleasure to congratulate and warmly welcome Dr. Tedros Adhanom Ghebreyesus as the new WHO Director General. Dr. Ghebreyesus, the former Minister of Health of Ethiopia, is the first WHO Director General from Africa.

I am pleased to welcome our newest Members, the University of Campinas and the University of São Paulo.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
**Special Announcement**

BVGH will be hosting the 3rd annual *Africa Pavilion* at the 2017 BIO International Convention in San Diego, June 19-22. If you will be at the Convention, please stop by the Pavilion and meet with scientists from five WIPO Re:Search Members – Addis Ababa University, the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), the Kenya Medical Research Institute (KEMRI), the Noguchi Memorial Institute for Medical Research (NMIMR), and the University of Buea – and potential new WIPO Re:Search Members.

Thank you to our Africa Pavilion sponsors:

![Pfizer](image1.png)  ![Takeda](image2.png)  ![Gilead](image3.png)  ![Genentech](image4.png)  ![Celgene](image5.png)  ![MSD](image6.png)

For more information, please email [Katy Graef](mailto:Katy.Graef@bvgh.org).

---

**WIPO Re:Search Statistics**

![Agreements and Members](chart.png)

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

---

**WIPO Re:Search Collaborations Involving an LMIC Member by Disease**

- Chagas disease (2.78%)
- Dengue (2.78%)
- Malaria (44.44%)
- Onchocerciasis (11.11%)
- Other (2.78%)
- Rabies (2.78%)
- Schistosomiasis (13.89%)
- Soil-transmitted helminthiases (2.78%)
- Tuberculosis (16.67%)
Cornerstones of Collaboration

Janssen Research & Development will provide Dr. Christina Stallings, Assistant Professor, Molecular Microbiology, Washington University in St. Louis (WUSTL), with its Jump-stARter library to screen against a *Mycobacterium tuberculosis* enzyme demonstrated to be essential for the growth and virulence of the bacterium. This genetically-validated enzyme is absent in eukaryotes and has yet to be pursued as a drug target.

New Member Announcement

We are pleased to announce that the University of Campinas and the University of São Paulo have joined WIPO Re:Search.

A public university funded by the state of São Paulo, the University of Campinas is a leading Brazilian university. The university is ranked #1 in Brazil in number of patents and number of articles published per faculty member. Scientists within the university perform research on the biochemistry, immunology, and cellular biology of *Leishmania* and the epigenetics of *Schistosoma* among others.

Founded in 1934, the University of São Paulo (USP) is one of Brazil’s most important universities. USP is responsible for over 20% of Brazil’s scientific outputs. The university is home to several departments – including the Institute of Tropical Medicine – conducting important research relevant to WIPO Re:Search. Examples of these research themes include malaria vectors and malaria epidemiology, dengue virus evolution, Chagas disease and leishmaniasis diagnostic biomarker discovery, and the immunopathogenesis of leishmaniasis.
**Partnership Hub Central**

WIPO and BVGH officially launched the *WIPO Re:Search Strategic Plan, 2017-2021* during the 2017 WIPO Re:Search biennial meeting, which was held last month in Geneva. BVGH and WIPO presented their respective activities and achievements in 2016-2017 and presented goals for the next five years. The new WIPO Re:Search resource platform was described and Members were updated on the capacity-building sabbatical program funded by IP Australia.

WIPO Re:Search was featured during the World Health Assembly at a side event coordinated by WIPO and the Special Programme on Tropical Disease Research (TDR). The program, “Building Capacity for Innovation and Access: Combating Neglected Tropical Diseases”, was sponsored by the Permanent Missions of Egypt, Bangladesh, Indonesia, Namibia, the Philippines, Singapore, and Switzerland, and was opened by Mr. Minelik Getahun, Assistant Director General, Global Issues Sector, WIPO. Dr. John Reeder, Director, TDR and WIPO Re:Search Advisory Committee Member, moderated the panel discussion. His Excellency, Amr Ramadan, Permanent Representative of Egypt to the United Nations Office and other International Organizations in Geneva, gave a special address.

The panel featured Dr. Effua Abigail Usuf, Medical Research Council UK and London School of Hygiene and Tropical Medicine (LSHTM) West African Global Health Research Fellow; Mr. Jon Pender, Vice President, Government Affairs, *GlaxoSmithKline* (GSK); and Jennifer Dent. Dr. Effua described her time as a research fellow at GSK. John Pender described GSK’s commitment to building low- and middle-income country (LMIC) research capacity as a critical component of advancing neglected infectious disease product development. Jennifer spoke about the impact WIPO Re:Search capacity building sabbaticals have had on six African researchers.

**BVGH FundFinder Featured Funding Announcement**

**Clinical Trial Award**

The Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on a disease or condition addressed in at least one of the Topic Areas (see below). Clinical trials may be designed to evaluate promising new products, pharmacologic agents, devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials through large-scale trials to determine efficacy in relevant patient populations. All studies must be responsive to the healthcare needs of the military service members, veterans, and/or beneficiaries; however, the use of military or veteran populations is not required.
Relevant Topic Areas include: emerging infectious diseases, malaria, tuberculosis, and vaccine development for infectious diseases.

**Funding amount:** No limit. The requested budget must be justified and appropriate to the scope of the clinical trial proposed.

**Funder:** US Department of Defense (DoD)

**Deadline:** July 20, 2017

**Eligibility:** All organizations, including international organizations, are eligible to apply. Principal investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit applications.

Click [here](#) to review other 2017 Peer Reviewed Medical Research Program (PRMRP) awards by the DoD.

For more information about BVGH FundFinder, please email [Cathy Manner](mailto:).  

---

**Highlighted Contributions**

Do you have an interest in screening a mini-collection of 80 diverse compounds? Would you like to access and screen any of the following inhibitors?

- PI3 kinase
- Hsp90
- Phosphodiesterase IV
- Phosphodiesterase V
- Calcium channel blockers

- Cathepsin
- Prostaglandin D synthase
- p53 (activators)
- Nicotinic acetylcholine receptor (agonists)
- Casein kinase

If so, please contact [Ujwal Sheth](mailto:) to learn more about these assets and to discuss your research idea.

---

**WIPO Re:Search in the News**

Interested in learning how people across the world are working to make schistosomiasis history? Click [here](#) to download the Global Schistosomiasis Alliance (GSA) report, *The people #MakingSchistory: The global fight against schistosomiasis*.
## Upcoming Global Health Meetings

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 19-22</td>
<td>2017 BIO International Convention</td>
<td>San Diego, California</td>
<td>Website</td>
</tr>
<tr>
<td>Sept. 10-14</td>
<td>Keystone Symposium: Vectors, Pathogens and Diseases: Current Trends and Emerging Challenges</td>
<td>Durban, South Africa</td>
<td>Website</td>
</tr>
<tr>
<td>Oct. 16-20</td>
<td>10th European Congress on Tropical Medicine &amp; International Health (ECTMIH)</td>
<td>Antwerp, Belgium</td>
<td>Website</td>
</tr>
</tbody>
</table>
In This Issue
WIPO Re:Search Statistics
Cornerstones of Collaboration
New Member Announcement
IP in Focus
Partnership Hub Central
Funding Announcement
Highlighted Contributions
WIPO Re:Search in the News
Upcoming Global Health Events

Letter from Jennifer

Dear WIPO Re:Search Members and Friends,

It is hard to believe we are now halfway through 2017! With the BIO International Convention and World Health Assembly behind us, BVGH and WIPO are making plans to expand our WIPO Re:Search capacity building activities and intellectual property (IP) support services.

IP is a core component of WIPO Re:Search and will now be featured in the Partnership Hub Snapshot. Please check out the new Snapshot section, IP in Focus, to learn more about the intersection of IP, research and development, and global health. Penned by WIPO, this section will also feature IP resources available to innovators through WIPO’s many programs.

I am pleased to welcome our newest Members, Seattle Children’s Research Institute and the University of Melbourne.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Cornerstones of Collaboration

BVGH coordinated the 3rd annual Africa Pavilion at the 2017 BIO International Convention in San Diego. Scientists from WIPO Re:Search Members, Addis Ababa University, the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), the Kenya Medical Research Institute (KEMRI), the Noguchi Memorial Institute for Medical Research (NMIMR), and the University of Buea, discussed their research interests and opportunities for partnership with other Convention attendees. Additional WIPO Re:Search Members, including the University of California, San Diego (UCSD), stopped by the Pavilion to discuss collaboration ideas with the exhibitors.
New Member Announcement

We are pleased to announce that Seattle Children’s Research Institute and the University of Melbourne have joined WIPO Re:Search.

Seattle Children’s Research Institute is driven by its mission to “provide hope, care, and cures to help every child live the healthiest and most fulfilling life possible.” Seattle Children’s conducts internationally-recognized research in genetics, infectious disease, immunology, and pathology, among others. The Center for Global Infectious Disease Research (CGIDR) and Center for Immunity and Immunotherapies (CIIT) at Seattle Children’s are home to scientists exploring a variety of research topics including host-mycobacteria interactions, a point mutation assay to detect drug-resistant HIV, and the study of immunogenicity vs. tolerance in the lungs.

Established in 1853, the University of Melbourne is Australia’s leading research-intensive university. University staff conduct numerous research projects relevant to WIPO Re:Search including snake venom proteomics; snake anti-venom research; lipopeptide-based adjuvants research; modular approaches to vaccine development using synthetic, semi-synthetic, and natural products; dengue diagnostic and prognostic tools development; malaria and leishmaniasis drug target identification; and Plasmodium gene regulation studies.
IP in Focus

The recently launched Strategic Plan 2017-2021 lays out WIPO Re:Search’s vision moving forward: improved global health through innovation that mobilizes intellectual property (IP) and the power of private and public sector collaborations. This vision grounds our work and is a recognition of the five years of achievements by Members. It is manifested in and guides the implementation of the four strategic goals that provide the framework through which WIPO Re:Search will continue to contribute to the evolving landscape of global health R&D in the coming five years.

The goals, in reflection of WIPO’s core mission, also re-emphasize the role of IP as a facilitator of innovation. In order to effectively bring them to life, WIPO plans to expand its IP-related activities, subject to funding. This will include developing services to provide WIPO Re:Search Members with input on IP management strategies (upon request), and working with BVGH to craft IP management frameworks around collaborations as they move further downstream.

Through this new section of the Snapshot, we will be taking the opportunity to regularly inform readers of the resources available to any researchers and innovators through other programs at WIPO, and to share relevant highlights of global developments around critical issues at the intersection of health, intellectual property, and access.

Please feel free to reach out to us with any ideas or requests for information and/or assistance. We look forward to hearing from you.

Anatole Krattiger
Director, Global Challenges Division, WIPO

Partnership Hub Central

The Chinese Pharmaceutical Innovation and Research Development Association (PhIRDA), which became the latest member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), visited WIPO last month. PhIRDA’s interests related to WIPO Re:Search, access to medicines, how China can contribute to Sustainable Development Goal (SDG) Number 3, and other relevant matters were discussed.

PhIRDA and WIPO representatives at WIPO’s offices in Geneva, Switzerland
BVGH FundFinder Featured Funding Announcement

EDCTP-GSK Senior Fellowships for Co-Morbidities between Poverty-Related Diseases and Non-Communicable Diseases

The purpose of this call is to provide funding to actions that aim to support capacity development of potential African research leaders using the train-the-trainer model and to mentor junior researchers with an emphasis on hands-on research training linked to clinical trials activities in sub-Saharan Africa in the area of prevention, therapeutic management, and prognosis of poverty-related diseases (PRDs) and non-communicable diseases (NCDs) co-morbidities.

The objectives of the scheme are two-fold:
- To support senior researchers to advance themselves as recognized research leaders in clinical trial research and related activities
- To equip senior researchers with the necessary skills and experience to train and mentor junior researchers at host institutions in sub-Saharan Africa.

Funding amount: €500,000 maximum over up to five years
Funder: European & Developing Country Clinical Trials Partnership (EDCTP) and GlaxoSmithKline (GSK)
Deadline: February 2, 2018
Eligibility: Open to established legal entities in sub-Saharan Africa. Fellow must have a minimum of five years’ relevant research experience after doctoral studies.

The EDCTP has announced 11 calls for proposals to support clinical research and capacity building in sub-Saharan Africa. These calls represent a total investment of more than €156.5M to tackle poverty-related diseases. Click here to view the full list of calls for proposals.

For more information about BVGH FundFinder, please email Cathy Manner.

Highlighted Contributions

Do you have an asset that you are willing to contribute to another WIPO Re:Search Member to further neglected tropical disease, malaria, or tuberculosis research and development? Email Ujwal Sheth to learn how you can have your asset summarized in the WIPO Re:Search Database and featured in an upcoming Snapshot newsletter.

WIPO Re:Search in the News

Johnson & Johnson (J&J) highlighted its commitment to sharing compound libraries to fight neglected infectious diseases in a recent press release. The release featured J&J’s WIPO Re:Search collaborations with the National Institutes of Health (NIH), Washington University in St. Louis (WUSTL), and the Walter and Eliza Hall Institute of Medical Research (WEHI).

Upcoming Global Health Meetings

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sept. 3-8</td>
<td>Molecular and Cellular Biology of Helminth Parasites</td>
<td>Hydra, Greece</td>
<td>Website</td>
</tr>
<tr>
<td>Oct. 25-27</td>
<td>COST Action: Chemotherapy Towards Diseases Caused by Endoparasites</td>
<td>Lausanne, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>Nov. 5-9</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 66th Annual Meeting</td>
<td>Baltimore, Maryland</td>
<td>Website</td>
</tr>
</tbody>
</table>
Copyright © 2017 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109
Dear WIPO Re:Search Members and Friends,

I am pleased to share the 2017 BVGH Partnership Hub Mid-Year Report with you! This report highlights BVGH’s activities and accomplishments towards our 2017 WIPO Re:Search goals and deliverables. Over the first half of the year, BVGH established seven new collaborations and one follow-on collaboration and recruited 19 new Members. Eight research training sabbaticals were coordinated and the WIPO Re:Search Strategic Plan, 2017-2021 was published. We continued to raise awareness of WIPO Re:Search through various communication channels and conferences.

The BVGH team have been busy updating the BVGH website and our brochure, which features WIPO Re:Search. Please send any comments to Mary Chaffee and let us know if you would like to schedule a time to update on WIPO Re:Search or any other topic.

I am pleased to welcome our newest WIPO Re:Search Members, the International Centre for Diarrhoeal Disease Research, Bangladesh; the National Institute for Medical Research; and the University of Dschang.

As always, please forward this Snapshot and our 2017 BVGH Partnership Hub Mid-Year Report to your colleagues and reach out to us with any partnering requests, ideas, or feedback.

Sincerely,
Jennifer Dent
President, BVGH
The Kectil Program is a web-based mentoring program dedicated to nurturing highly-talented youth in developing countries who have the potential to make an impact on their communities and countries. The program consists of 12 sessions, divided into five sections: introduction and mission, leadership skills, innovation and entrepreneurship, case studies, and wrap-up and what’s next. The program is open to youth (aged 17-26) based in a developing country. The application for the Kectil Program will open on August 15, 2017.

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

Takeda Pharmaceutical Co., Ltd. will provide Dr. Judy Sakanari, Adjunct Professor, Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), with four preclinical/clinical-stage compounds to screen against Brugia pahangi.
We are pleased to announce that the International Centre for Diarrhoeal Disease Research, Bangladesh; the National Institute for Medical Research; and the University of Dschang have joined WIPO Re:Search.

Originally established as the South-East Asia Treaty Organization (SEATO) Cholera Research Laboratory in 1960, the organization was renamed the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) in 1978 and its research directive was expanded to include the major public health threats facing Bangladesh and other countries in the global South. Research performed at icddr,b includes assessing *P. falciparum* drug resistance and malaria point-of-care diagnostics, epidemiology of drug resistant *M. tuberculosis*, improving tuberculosis infection control practices, and identifying new tuberculosis vaccine candidates.

Based in Dar es Salaam, Tanzania, the National Institute for Medical Research (NIMR) is a parastatal organization functioning under the Tanzanian Ministry of Health. As the largest health research institution in Tanzania, NIMR staff perform research on a variety of topics relevant to WIPO Re:Search including human African trypanosomiasis (HAT) epidemiology; drug sensitivity and characterization of *T. brucei* isolates; maintenance of a *T. brucei* specimen bank; natural products studies; and malaria transmission-blocking drug discovery.

Located in western Cameroon, the University of Dschang is one of Cameroon’s eight state universities. The University’s goal is to provide training to its ~35,000 students that meets the country’s development needs. Researchers within the Faculty of Science perform human African trypanosomiasis (HAT) drug discovery, HAT and African animal trypanosomiasis (AAT) control and “one health” research, and tuberculosis drug discovery, among others.

**IP in Focus**

The [World Intellectual Property Organization](http://www.wipo.int) (WIPO) provides innovators in business and academia a range of cost-effective services to protect their invention, brands, and designs in multiple countries.

A newly launched initiative in collaboration with the World Economic Forum, is the [Inventor Assistance Program](http://www.wipo.int) (IAP) – the first global program of its kind. IAP matches developing country inventors with limited financial means from both public and private sector institutions, with patent attorneys willing to provide pro bono legal assistance to secure national and regional patent protection for their inventions. Knowledge of the patent system and corresponding administrative procedures is crucial in order to obtain patent rights for one’s invention. Therefore, to navigate the patent system effectively, expert advice is often key.

The IAP has been launched in Colombia, Morocco, and the Philippines and measures are being taken to expand the program to other countries. Researchers in public sector organizations and small- and medium-sized enterprises in developing countries may receive the necessary support to protect their intangible assets thanks to this new initiative. To date, more than 15 inventors have benefited from this program and 59 patent attorneys have joined. The IAP counts with the sponsorship of several institutions and corporations including the Inter-American Association of Intellectual Property (ASIPI), the International Federation of Inventors’ Associations (IFIA), Novartis, Qualcomm, Pfizer, the European Patent Institute (EPI), and the United States Federal Circuit Bar Association (FCBA).

A recent [WIPO Magazine](http://www.wipo.int) article offers additional information about how this service supports national innovation goals and enhances the national patent systems, thus contributing to economic growth.

Anatole Krattiger
Director, Global Challenges Division, WIPO
Beckman Young Investigator (PYI) Program
The Beckman Young Investigator (BYI) Program provides research support to the most promising young faculty members in the early stages of their academic careers in the chemical and life sciences, particularly to foster the invention of methods, instruments, and materials that will open up new avenues of research in science. Projects proposed for the BYI Program should be truly innovative, high-risk, and show promise for contributing to significant advances in chemistry and the life sciences. They should represent a departure from current research directions rather than an extension or expansion of existing programs. Proposed research that cuts across traditional boundaries of scientific disciplines is encouraged.

Funding amount: ~$600,000 over four years
Funder: Arnold and Mabel Beckman Foundation
Deadline: Letter of Intent due August 14, 2017
Eligibility: Applicants must be within the first three years of a tenure-track position at the time of application. The BYI Program is open to citizens or permanent residents of the United States of America.

For more information about BVGH FundFinder, please email Cathy Manner.

Highlighted Contributions

Do you have a screening assay for malaria, tuberculosis, or NTD drug discovery? Would you like to access and screen any of the following inhibitors?

- 5-Lipoxygenase (LOX)
- Angiotensin II
- Calcium channel blockers
- Carbonic anhydrase
- Dihydrofolate reductase (DHFR)
- Glutamate antagonist
- Intracellular adhesion molecule 1 (ICAM-1)
- Kinase (including receptor tyrosine kinase)
- Monoamine oxidase (MAO)
- Peroxisome proliferator-activated receptor
- Phosphodiesterase (PDE) V
- Platelet activating factor
- Poly ADP-ribose polymerase (PARP)
- Protease-activated receptor PAR-1
- Proteasome
- Sodium channel antagonist
- Squalene synthase
- Thromboxane A2 synthase 1 (TBXAS1)
- TLR4 agonist

If so, please contact Ujwal Sheth to learn more about these assets and to discuss your research idea.
## Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 5-9</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 66th Annual Meeting</td>
<td>Baltimore, Maryland</td>
<td><a href="#">Website</a></td>
</tr>
<tr>
<td>Mar. 1-4</td>
<td>18th International Congress on Infectious Diseases (ICID)</td>
<td>Buenos Aires, Argentina</td>
<td><a href="#">Website</a></td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada*
Dear WIPO Re:Search Members and Friends,

It has been an exciting month for WIPO Re:Search Members. The International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) was awarded this year’s Hilton Humanitarian Prize by the Conrad N. Hilton Foundation. Past award recipients include The Task Force for Global Health, PATH, and Partners in Health. Congratulations to icddr,b!

The US Food and Drug Administration (FDA) approved Chemo Research’s new drug application for benznidazole to treat Chagas disease. Drugs for Neglected Diseases initiative (DNDi) provided technical expertise and clinical trials data to support the new drug application.

Novartis and Medicines for Malaria Venture (MMV) have launched a Phase IIb clinical trial of a next-generation antimalarial (KAF156) with the potential to treat drug-resistant strains of Plasmodium.

Please join WIPO and BVGH at the 2017 WIPO General Assemblies where IP Australia is hosting a WIPO Re:Search FIT2 sabbatical program side event. I will be presenting an update on the FIT2 sabbatical program alongside WIPO and one of our FIT2 fellows. Cathy Manner and Mary Chaffee will be representing BVGH at the 66th American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting in Baltimore, Maryland this November. Please reach out to Cathy or Mary to arrange a time to meet during the conference.

I am pleased to welcome our newest WIPO Re:Search Members, Université Paris-Sud and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
Janssen, the Pharmaceutical Companies of Johnson & Johnson, is hosting a symposium to discuss the latest in Chagas disease research. The event will take place on December 5, 2017 in San Diego, California and will feature several seminars followed by a roundtable discussion lead by Dr. Jim McKerrow, Dean, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego (UCSD).

To register for this event, click here.

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here.

Click here to view a complete list of WIPO Re:Search Members.

Eisai Co., Ltd. will provide Prof. Mike Pollastri, Professor & Chair, Department of Chemistry & Chemical Biology, Northeastern University (NEU), and Prof. Jim McKerrow, Director, and Prof. Jair Siqueira-Neto, Kinetoplastid and High Throughput Screening Facility Core Director, Center for Discovery and Innovation in Parasitic Diseases (CDIPD), University of California, San Diego (UCSD), with a targeted set of inhibitors – and their structures – to screen against T. cruzi and Leishmania spp.. Prof. McKerrow and Prof. Siqueira-Neto will perform in vitro screens against the parasites and Prof. Pollastri will perform subsequent lead optimization studies.
We are pleased to announce that Université Paris-Sud and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine have joined WIPO Re:Search.

Established in 1971, Université Paris-Sud (UPSud) is now one of the largest universities in France. UPSud has five major training and research units that support 2,500 teachers and researchers across 78 laboratories. UPSud’s WIPO Re:Search-relevant research activities include diagnostic development for diseases such as tuberculosis, and extensive efforts to accelerate therapeutic innovation for parasitic diseases including leishmaniasis and malaria. UPSud faculty have access to excellent technology platforms including imaging and flow cytometry, high-throughput screening platforms, and molecular pharmacology, as well as animal and functional exploration, among others.

Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) is a product development partnership and the research arm of the National School of Tropical Medicine (NSTM) at Baylor College of Medicine. NSTM and Texas Children’s CVD relocated in 2011 from the Washington DC area with a purpose to expand its remit and exclusively address population health, translational research and biotechnology, training, and health policy and outreach needs to tackle the world’s poverty-related neglected and emerging tropical diseases.

Texas Children’s CVD has a track record in bringing three different vaccines against human hookworm infection and one vaccine against schistosomiasis from the research and development stages through production and regulatory approval, and into first-in-human clinical trials. Currently, Texas Children’s CVD is advancing these vaccines into proof-of-concept Phase II clinical trials and has a portfolio of an additional half-dozen vaccines being transitioned from the bench into the clinic including Chagas disease, leishmaniasis, onchocerciasis, and Middle East respiratory syndrome (MERS).

Texas Children’s CVD is also interested in partnering to advance vaccine development for neglected tropical diseases (NTD) and building vaccine capacity and training globally. For example, Texas Children’s CVD has partnered with institutions in Saudi Arabia, Malaysia, Mexico, and Brazil and it recently partnered with MilliporeSigma (the life science division of Merck KGaA, Darmstadt, Germany) to optimize vaccine manufacturing and improve vaccine stability, with the intention of accelerating NTD vaccines’ development and delivery to those in need.

IP in Focus

In an era of decreased financial support from traditional sectors, universities and research institutions often explore strategies that leverage intellectual property (IP) assets. Institutional IP policies serve as a foundation by outlining how an institution intends to deal with the ownership and disposition of its IP, thus protecting and increasing the value of research generated by its scientists. IP policies are also important for a number of other reasons. They are fundamental in helping institutions realize ethical and social commitments, balance the generation and use of IP with their public sector mission, and especially, ensure the dissemination of knowledge through teaching, publications, research, and technology transfer. For these reasons, a comprehensive policy will serve the mission of the institution and strengthen its credibility, reputation, and public image. While the policy development process is in itself a valuable undertaking, it is only the first step toward successful technology transfer, which also requires reasonable expectations, patience, and buy-in from senior management.
The World Intellectual Property Organization (WIPO) provides capacity building programs and tools to support the development of IP Policies for Universities and Research Institutions. Available resources include a list of frequently asked questions, a database of real world IP policies, manuals, and agreements from over 70 countries, as well a variety of free documents and practical guidelines. By the end of 2017, this webpage will also contain IP policy templates, guidelines for customization, a policy writer’s checklist, and an IP commercialization tool box. WIPO also hopes to develop a database of relevant national legal and regulatory frameworks, providing an overview of national rules on ownership and commercialization of IP generated at universities and research institutions.

Would you like to add your institutional IP policy to the WIPO Database? Do you have any questions? Contact us at re_search@wipo.int.

Anatole Krattiger  
Director, Global Challenges Division, WIPO

---

FIT2 trainee Ms. Dulcie Lautu, Graduate Student, Papua New Guinea Institute of Medical Research (PNGIMR), has started her five-month sabbatical in the lab of Professor Alyssa Barry, Laboratory Head, Population Health and Immunity Division, Walter and Eliza Hall Institute of Medical Research (WEHI). During her sabbatical, Ms. Lautu will focus on molecular surveillance of and the development of genomic tools for malaria. Ms. Lautu’s sabbatical is supported by funding from IP Australia to WIPO through Funds in Trust (FIT).

Pew Latin American Fellows Program  
The Pew Latin American Fellows Program in the Biomedical Sciences provides support for young scientists from Latin America to receive postdoctoral training in the United States. The program gives individuals an opportunity to further their scientific knowledge by promoting exchange and collaboration between investigators in the United States and Latin America resulting in advances in research in Latin America.

Funding amount: $30,000 USD stipend/year for two years and $70,000 for lab supplies and equipment upon return to Latin America  
Funder: The Pew Charitable Trusts  
Deadline: October 2, 2017  
Eligibility: Applicants must have been awarded a PhD and/or MD by February 2018, but not more than five years prior to July 2018

For more information about BVGH FundFinder, please email Cathy Manner.
Tres Cantos Open Lab Foundation: accelerating the discovery of medicines for diseases of the developing world

The Tres Cantos Open Lab Foundation (TCOLF) is a charity that supports drug discovery-oriented projects in malaria, tuberculosis, kinetoplastids, and *Shigella* infections. TCOLF will fund collaborative research projects between applicants and GlaxoSmithKline (GSK) Diseases of the Developing World Medicines Development Campus in Tres Cantos, Spain. Grantees will have access to GSK’s scientific knowledge and resources (screening, medicinal chemistry, and *in vitro* and *in vivo* disease models including BSL-3 labs) to advance their research. Proposals are accepted on a rolling basis. The next evaluation meeting will be held on November 20, 2017. Click [here](#) for more information.

Get involved and make a difference in your research!

Highlighted Contribution

According to the WHO, between 2010 and 2015, malaria incidence fell by 21% globally. Despite this impressive decline, malaria is still endemic in 91 countries and accounts for an estimated 200+ million cases annually, resulting in approximately 430,000 deaths – primarily in children under the age of five. This mosquito-borne illness claims the life of one child every two minutes.

In recognition of World Mosquito Day (August 20th), this Snapshot highlights compounds that have demonstrated repurposing potential against *Plasmodium* parasites:

- Diglyceride acyltransferase (DGAT) 1 inhibitors
- Enhancer of zeste homolog (EZH) 2 (histone-lysine N-methyltransferase) inhibitors
- Histone deacetylase (HDAC) inhibitors
- HIV protease inhibitors
- HMG-CoA Reductase inhibitors
- Lysine-specific demethylase (LSD) 1 inhibitors

For more information or to discuss accessing these inhibitors, please contact Mary Chaffee.

Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Web Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 5-9</td>
<td>American Society of Tropical Medicine &amp; Hygiene (ASTMH) 66th Annual Meeting</td>
<td>Baltimore, Maryland</td>
<td>Website</td>
</tr>
<tr>
<td>Dec. 5</td>
<td>Chagas Disease: Current Status and Future Therapeutic Directions</td>
<td>San Diego, California</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 28 – Feb.1</td>
<td>Keystone Symposium: Emerging Technologies in Vaccine Discovery and Development</td>
<td>Banff, Canada</td>
<td>Website</td>
</tr>
</tbody>
</table>
Copyright © 2017 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109
Dear WIPO Re:Search Members and Friends,

As the end of the year rapidly approaches, BVGH is intensifying its planning and preparation for 2018 and beyond. During the WIPO General Assemblies last week in Geneva, BVGH and WIPO met with representatives of the WIPO Re:Search Advisory Committee to discuss the implementing activities of the WIPO Re:Search Strategic Plan. Securing funding for WIPO Re:Search collaborations and sabbaticals as well as new company Member recruitment will be prioritized in 2018. BVGH is enthusiastic to be working with our partners to expand the impact and global visibility of WIPO Re:Search.

I encourage you to review this month’s BVGH FundFinder Featured Award from the National Institutes of Health (NIH), which supports therapeutic discovery through repurposed, targeted pharmaceutical libraries. Please reach out to us if you would like to explore a WIPO Re:Search partnership around this funding opportunity.

The 66th ASTMH Annual Meeting is just around the corner and our team are looking forward to meeting with many of our WIPO Re:Search Members there. In addition to ASTMH, BVGH will be attending Janssen’s R&D symposium on Chagas Disease: Current Status and Future Therapeutic Directions. If you are interested in attending the Chagas meeting, click here to register. Please email Cathy Manner or Mary Chaffee to arrange a meeting at either of these events.

Next month, WIPO, the Access to Medicine Foundation, and the World Health Organization (WHO) will be hosting a seminar on accelerating innovation and access to vaccines. Please click here to register for this event.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,

Jennifer Dent
President, BVGH
**Tres Cantos Open Lab Foundation: accelerating the discovery of medicines for diseases of the developing world**

The Tres Cantos Open Lab Foundation (TCOLF) is a charity that supports drug discovery-oriented projects in malaria, tuberculosis, kinetoplastids, and *Shigella* infections. TCOLF will fund collaborative research projects between applicants and GlaxoSmithKline (GSK) Diseases of the Developing World Medicines Development Campus in Tres Cantos, Spain. Grantees will have access to GSK’s scientific knowledge and resources (screening, medicinal chemistry, and *in vitro* and *in vivo* disease models including BSL-3 labs) to advance their research. Proposals are accepted on a rolling basis. The next evaluation meeting will be held on November 20, 2017. Click [here](#) for more information.

*Get involved and make a difference in your research!*

---

**WIPO Re:Search Statistics**

- **34** Active Agreements
- **120** Agreements Established
- **127** Members
- **38** Countries
- **4** Advancing Agreements

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click [here](#).

Click [here](#) to view a complete list of WIPO Re:Search Members.

---

**Cornerstones of Collaboration**
Through *in vitro* screens, Professor Fabrice Boyom, Head, Antimicrobial and Biocontrol Agents Unit (AmBcAU), *University of Yaoundé I*, has identified several Cameroonian fungi and medicinal plant fractions and pure compounds with promising activity and selectivity against *M. ulcerans*, *Leishmania spp.*, *T. brucei*, and *S. mansoni*. To help advance these products’ development as potential drugs, Professor Bill Baker, Chemistry Department, *University of South Florida* (USF), will attempt to isolate, characterize, and elucidate the structures of these natural products.

**Patent Information Initiative (Pat-INFORMED)**

WIPO is pleased to introduce the Patent Information Initiative for Medicines or “Pat-INFORMED”, a multi-stakeholder platform established in cooperation with the *International Federation of Pharmaceutical Manufacturers and Associations* (IFPMA) and 20 of its leading global research-based pharmaceutical company members. Pat-INFORMED aims to improve access to patent information for registered medicines by offering the tools and information that health professionals need for specific products and countries.

Health policy advocates and national authorities have long called for making patent information more accessible, especially for the purpose of facilitating the procurement of medicines. Up until now, this information has been stored in the registers of national and regional patent offices or through third-party databases, which are complex and difficult to access for non-specialists, as well as limited in territorial scope.

As announced October 3, 2017 during the General Assemblies of WIPO, Pat-INFORMED will share patent information on a public database. In addition to this, participating companies agree to provide more detailed information in response to requests from procurement agencies. During the first phase of this initiative, the public database will focus on small molecule products related to oncology, hepatitis C, cardiovascular, HIV, diabetes and respiratory therapy areas, and any product on the *WHO Model List of Essential Medicines* not within these areas. The second phase will seek to expand this information to all therapy areas for small molecules.

“Pat-INFORMED will make it easier for procurement experts to assess the patent status of medicines, underlining how a well-designed and implemented patent system incentivizes innovation while making available and accessible key information about patented inventions,” said WIPO Director General Francis Gurry.

For more information about this exciting new initiative, please contact Thomas Bombelles, Head, Non-Governmental Organizations and Industry Relations Sections.

---

*Anatole Krattiger*

*Director, Global Challenges Division, WIPO*
Jennifer Dent and Edward Kwakwa, Senior Director, Department for Traditional Knowledge and Global Challenges, WIPO, introduced WIPO Re:Search and its training sabbatical program during an Australian Funds in Trust (FIT) side event during the 57th WIPO General Assembly. The event, which was opened by Dr. Francis Gurry, Director General, WIPO, and Patricia Kelly, Director General, IP Australia, also featured presentations of two additional Australian FIT projects, FIT Technology Transfer Initiative and Accessible Books Consortium (ABC) project.

Repurposing Target-Based Pharmaceutical Libraries for Discovery of Therapeutics against Eukaryotic Pathogens (R21/R33)

The purpose of this opportunity is to support whole cell and/or high-throughput screening of target-based pharmaceutical libraries to identify potential therapeutics against select eukaryotic pathogens, and their subsequent preclinical development. Pathogens of interest include, but are not limited to: Leishmania spp., Plasmodium spp., Trypanosoma spp., and helminths. Priority will be given to projects that focus on one or more pathogens for which therapeutic options are limited or compromised by antimicrobial resistance. Projects focused on Plasmodium spp. are restricted to therapeutics against multiple-drug-resistant forms.

Funding amount: $275,000 over the two-year R21 phase (maximum of $200,000/year). $300,000/year for up to three years for the R33 phase.

Funder: National Institutes of Health (NIH)
Deadline: Letter of intent due December 12, 2017
Eligibility: U.S. and foreign organizations

For more information about BVGH FundFinder, please email Cathy Manner.
The United States Patent & Trademark Office (USPTO) is accepting applications for its Patents for Humanity award. This award recognizes patent holders who are pioneering innovative ways to provide affordable, scalable, and sustainable solutions for the less fortunate. Winners receive public recognition of their work and an acceleration certificate to expedite certain matters before the USPTO: a patent application, ex parte re-exam, or an ex parte appeal to the Patent Trial and Appeal Board.

**Soil-transmitted helminths**

Soil-transmitted helminth (STH) infections afflict an estimated 1.5 billion people worldwide (over 20% of the world’s population). In poverty-stricken regions of Africa, India, South America, and Southeast Asia, as many as 66% of children are infected. Infection can occur when children ingest eggs after playing in contaminated soil and put their hands in their mouths without washing them. STH infections can lead to both physical and cognitive impairment.

Although treatments exist, anthelmintic resistance (AR) is of growing concern. Over the last four years, mass drug administration (MDA) coverage for STHs has doubled from 30 to 60%. This widespread drug administration increases the risk of AR, as drugs used for MDA initiatives rely on a single mode of action and are administered in suboptimal doses. As such, there is a great need for the development of alternative drugs with novel mechanisms of action.

In recognition of World Handwashing Day (October 15th), this Snapshot highlights compounds that have demonstrated repurposing potential against soil-transmitted helminths.

- Cathepsin inhibitors
- Histamine I receptor antagonists
- Inhibitors of microtubule polymerization
- Nicotinic acetylcholine receptor agonists
- 5-lipoxygenase inhibitors

For more information or to discuss accessing these compounds, please contact Mary Chaffe.

**WIPO Re:Search in the News**

**57th WIPO General Assembly**

At the 57th WIPO General Assembly in Geneva last week, WIPO Director General Francis Gurry highlighted WIPO’s involvement in public-private partnerships, as encouraged by the United Nations Sustainable Development Goals (SDGs). During the address, Dr. Gurry called special attention to SDG 17, which underscores the importance of revitalizing global partnerships to strengthen overall SDG implementation, citing WIPO Re:Search as one of WIPO’s key public-private partnerships contributing to achieving this SDG. Director General Gurry’s opening remarks were featured in Intellectual Property Watch.
# Upcoming Global Health Events

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 5 - 9</td>
<td>66th American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting</td>
<td>Baltimore, Maryland</td>
<td>Website</td>
</tr>
<tr>
<td>Nov. 8</td>
<td>Global Challenges Seminar on Vaccines: Accelerating Innovation and Access</td>
<td>Geneva, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>Dec. 5</td>
<td>Chagas Disease: Current Status and Future Therapeutic Directions</td>
<td>San Diego, California</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 30 - Feb. 2</td>
<td>Anthelmintics III: From Discovery to Resistance</td>
<td>Indian Rocks Beach, Florida</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada

Copyright © 2017 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109
Dear WIPO Re:Search Members and Friends,

As we call attention to World Antibiotic Awareness Week (Nov. 13-19th), we recognize antimicrobial resistance (AMR) as a growing concern that requires action from multiple global public health stakeholders. In support of this action, WIPO published a report underscoring the need to address AMR, and calling for support of R&D towards novel diagnostics and treatments.

WIPO Re:Search is responding to the AMR crisis by establishing collaborations between Members to accelerate the development of novel drugs and resistance-detecting technologies for neglected infectious diseases including those that address diagnostic and therapeutic gaps for soil-transmitted helminthiases, malaria, and tuberculosis.

I am pleased to welcome our two newest Members, Institute of Molecular and Cellular Biology of Rosario (IBR) and George Washington University.

Have you presented or published the results of your WIPO Re:Search collaboration recently? If so, please let Katy Graef know so that BVGH can feature your work in the 2017 WIPO Re:Search Annual Report, as well as in an upcoming issue of the Snapshot.

As always, please forward this Snapshot to your colleagues and reach out to us with any partnering requests or ideas.

Sincerely,
Jennifer Dent
President, BVGH
Chagas Disease: Current Status and Future Therapeutic Directions

Janssen, the Pharmaceutical Companies of Johnson & Johnson, is hosting a symposium to discuss the latest in Chagas disease research. The event will take place on December 5, 2017 in San Diego, California and will feature several seminars followed by a roundtable discussion lead by Dr. Jim McKerrow, Dean, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego (UCSD).

Please click here to register, and email Cathy Manner to arrange a meeting at the event.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here. Click here to view a complete list of WIPO Re:Search Members.

Cornerstones of Collaboration

In follow-up to a prior agreement, Eisai Co., Ltd. will provide Prof. Jim McKerrow, Director, and Prof. Jair Siqueira-Neto, Kinetoplastid and High Throughput Screening Facility Core Director, Center for Discovery and Innovation in Parasitic Diseases (CDIPD), University of California, San Diego (UCSD), with additional squalene synthase inhibitors to test against T. cruzi and Leishmania spp. Eisai has also agreed to provide Prof. Conor Caffrey, Nematode and Trematode Core Director, CDIPD, with two targeted inhibitor sets to screen against S. mansoni.
FIT2 fellow Tahmina Ahmed from the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) has begun her sabbatical with Prof. Leann Tilley and Dr. Natalie Spillman at the University of Melbourne. The sabbatical is supported by funding from IP Australia to WIPO through Funds in Trust (FIT). Tahmina’s project is focused on investigating the antimalarial activities of select inhibitors. From left to right: Dr. Natalie Spillman, Prof. Leann Tilley, and Tahmina Ahmed.

We are pleased to announce that the Institute of Molecular and Cellular Biology of Rosario (IBR) and George Washington University have joined WIPO Re:Search.

Institute of Molecular and Cellular Biology of Rosario

The Institute of Molecular and Cellular Biology of Rosario (IBR) was founded in 1999 as a joint effort between the Argentinian National Scientific and Technical Research Council (CONICET) and the University of Rosario. Laboratories at IBR span a diverse range of research interests including mechanisms of bacterial pathogenesis and resistance and the biology and biochemistry of Trypanosoma cruzi. IBR contributes to scientific innovation through specialized services including cellular toxicity assays and structural biology and metabolomics technology platforms.

George Washington University

The George Washington University (GW) was established in 1821, and is the largest institution of higher education in Washington D.C. The University includes 10 schools, over 1,200 non-medical, and more than 1,000 medical faculty. Researchers in GW’s Department of Microbiology, Immunology, and Tropical Medicine (MITM) conduct innovative, fundamental, basic, and translational research for a host of NTDs. Research conducted by GW faculty includes drug discovery for tuberculosis, development of a hookworm vaccine, identification of biomarkers for Schistosoma-related cancers, and identification of drug targets in African trypanosomes.

WIPO TISCs – Accessing the information most relevant to you

For many innovators, knowing where to find the necessary patent, scientific, and technological resources to take their innovation forward can prove challenging. Addressing this issue is one of the main goals of the IP in Focus series. Yet going through a technical database with millions of records begs the following question about accessibility of information – how can you find and identify the information most relevant to you?
To help address this question, WIPO has teamed up with national and regional intellectual property offices to support the establishment and development of Technology and Innovation Support Centers (TISCs). TISCs are designed to provide developing country innovators with access to locally-based, high quality technology information services and other related support. Services include facilitated access to patent databases and other scientific and technology resources through tailored support with information search and retrieval, on-demand searches, and monitoring of technology and competitors (who might also become collaborators). Users can also benefit from access to information on relevant laws, management and strategy, and commercialization and marketing.

Additional services include on-site training and distance learning as well as dissemination of best practices and experiences. Currently, over 70 WIPO Member States are in the process of establishing TISC networks that encompass more than 600 individual centers.

For more information please visit the TISC web page at www.wipo.int/tisc. You can also browse the “eTISC” knowledge management platform to access social media tools and new services and resources and join the online global TISC community at http://etisc.wipo.org.

Anatole Krattiger
Director, Global Challenges Division, WIPO

---

**66th Annual Meeting of the American Society of Tropical Medicine & Hygiene**

Cathy Manner and Mary Chaffee represented BVGH at the ASTMH Annual Meeting November 5-9 in Baltimore, Maryland. Cathy and Mary discussed WIPO Re:Search collaboration ideas with Members from Cheikh Anta Diop University, the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), McGill University, MSD*, Medicines for Malaria Venture (MMV), National Institute for Medical Research (NIMR), the National Institutes of Health (NIH), PATH, the University of California (San Diego and San Francisco), the University of Georgia (UGA), and others.

*Known as Merck & Co., Inc. in the US and Canada
Promoting Policy Coherence on Health Technology Innovation & Access in the ARIPO Region

Charles Randolph, Head, Global Health, WIPO, attended the High Level Meeting on Promoting Policy Coherence on Health Technology Innovation and Access for the African Regional Intellectual Property Office (ARIPO), held Nov. 1-3 in Lilongwe, Malawi. During the panel, Charles (left) had the opportunity to meet with His Excellency the Ambassador Robert D. Salama (center), and the Malawi Minister of Health, Honorable Atupele Austin Muluzi (right).

Inclusiveness Target Countries (ITC) Conference Grant

COST is the longest-running European framework supporting trans-national cooperation among researchers, engineers, and scholars across Europe. The COST Association complements the activities of the European Union Framework Programmes, fostering connections with the scientific communities of COST Inclusiveness Target Countries (ITCs). The COST Association recently allocated ~€5,600 towards "Inclusiveness Target Countries Conference Grants" to allow four Ph.D. students or early-career investigators from ITCs to attend international science and technology conferences. Eligible conferences do not need to be organized by a COST Action.

**Funding amount:** €1,400  
**Funder:** COST  
**Deadline:** 45 days before the conference start date. The event should take place before March 11, 2018.  
**Eligibility:** Ph.D. students or early career investigators affiliated with an institution located in an ITC.

1 The following countries are considered ITC: Bosnia-Herzegovina, Bulgaria, Cyprus, Czech Republic, Estonia, Croatia, Hungary, Lithuania, Latvia, Luxembourg, Malta, Montenegro, Poland, Portugal, Romania, Slovenia, Slovakia, the former Yugoslav Republic of Macedonia, Republic of Serbia and Turkey.

For more information about BVGH FundFinder, please email Cathy Manner.

Tuberculosis

In the last 100 years, the discovery of antibiotics, beginning with penicillin, revolutionized human health and society. Today, we can easily treat infections that once took tens of thousands of lives. Many organisms, however, have begun to show signs of antimicrobial resistance (AMR), threatening to once again pose grave dangers to human health. *Mycobacterium tuberculosis* is one such organism that has followed this concerning trend. Recent years have seen the introduction of multidrug resistant tuberculosis strains (MDR-TB), and even extreme drug-resistant strains (XDR-TB), unresponsive to at least one of three second-line drugs.

The success rate of MDR-TB treatment is only around 50%, and drops to around 25% for XDR-TB. There is an urgent need for new tuberculosis drugs with novel targets and mechanisms of action.
In recognition of World Antibiotic Awareness Week (Nov. 13-19th), this Snapshot highlights compounds that have repurposing potential against tuberculosis:

- Carbonic anhydrase inhibitors
- CXCR2 antagonists
- HDAC inhibitors
- Proteasome inhibitors
- STING inhibitors

For more information or to discuss accessing these compounds, please contact Mary Chaffee.

<table>
<thead>
<tr>
<th>Dates</th>
<th>Event Name</th>
<th>Location</th>
<th>Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov. 23</td>
<td>ISNTD Water 2017</td>
<td>London, UK</td>
<td>Website</td>
</tr>
<tr>
<td>Dec. 7 - 8</td>
<td>Swiss TPH Winter Symposium: Helminth Infection - from Transmission to Control</td>
<td>Basel, Switzerland</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 28 - Feb. 1</td>
<td>Keystone Symposium: Emerging Technologies in Vaccine Discovery and Development (J5)</td>
<td>Banff, Alberta</td>
<td>Website</td>
</tr>
<tr>
<td>Jan. 30 - Feb. 2</td>
<td>Anthelmints III: From Discovery to Resistance</td>
<td>Indian Rocks Beach, Florida</td>
<td>Website</td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada

Copyright © 2017 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109
Dear WIPO Re:Search Members and Friends,

As 2017 draws to a close, BVGH celebrates with you, the WIPO Re:Search community, the many exciting achievements this year has brought. WIPO Re:Search membership has grown to include more than 130 organizations representing 40 countries. In 2017 alone, we welcomed 25 new Members to the Consortium. BVGH established 14 new targeted collaborations this year, with many more under discussion.

In the World Malaria Report 2017, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus cautions that although global malaria cases have decreased since 2010, the rate of decline has decelerated, and even reversed in some regions. The report highlights the causes of this deceleration, including the lack of consistent funding and the emergence of antimalarial resistance, which jeopardize our progress towards elimination. We cannot afford to lose more ground and cede progress made. In order to regain a foothold against malaria, we must bolster research and funding towards the development of new diagnostics, vaccines, and antimalarials. I encourage you to read this Snapshot’s “Highlighted Contributions” section, which features several compound classes with demonstrated repurposing potential for malaria. If you are interested in assessing these – or other – inhibitor types against Plasmodium parasites, please reach out to Cathy Manner.

I am pleased to welcome our newest WIPO Re:Search Member, the Centre for Plant Medicine Research.

Have you presented or published the results of your WIPO Re:Search collaboration in 2017? If so, please let Katy Graef know so that we can feature your efforts in the 2017 WIPO Re:Search Annual Report, as well as in an upcoming issue of the Snapshot.

As we look forward to 2018, the BVGH team thanks you for your ongoing support and participation in WIPO Re:Search. We wish you the very best over the holiday season and into the New Year.

Sincerely,
Jennifer Dent
President, BVGH
Gates Open Research: Immediate & Transparent Publishing

In 2017, the Bill & Melinda Gates Foundation underscored its commitment to transparency through the announcement of its new initiative, Gates Open Research. Gates Open Research provides Gates-funded investigators with the option to accelerate the publication of their research findings. Over ten articles have already been released since Gates Open Research launched last month.

Are you a Gates-funded researcher interested in utilizing this resource? Submit your research here.

WIPO Re:Search Statistics

To view a current summary of the WIPO Re:Search agreements by disease and stage of development, click here. Click here to view a complete list of WIPO Re:Search Members.

Cornerstones of Collaboration

Building on an existing collaboration, funded by the Tres Cantos Open Lab Foundation (TCOLF), Dr. Yossi Av-Gay, Professor of Infectious Disease at the University of British Columbia (UBC), screened GlaxoSmithKline (GSK) compounds against M. tuberculosis (MTB) in host macrophages. Through the screen, Dr. Av-Gay identified a set of small molecules that had activity against MTB within macrophages, but did not directly kill the bacteria in culture. Through WIPO Re:Search, GSK will now collaborate with Dr. Jeffery Cox, C.H. Li Chair of Biochemistry & Molecular Endocrinology and Professor of Immunology & Pathogenesis at the University of California, Berkeley (UCB) who will use novel microscopic assays to assess whether the compounds activate autophagy – a host pathway involved in controlling MTB infection.
There is great need to develop new therapeutics against Chagas disease, human African trypanosomiasis, and leishmaniasis. To support drug development efforts, **Merck KGaA, Darmstadt, Germany** will provide Prof. Jim McKerrow, Director, and Prof. Jair Siqueira-Neto, Kinetoplastid and High Throughput Screening Facility Core Director, **Center for Discovery and Innovation in Parasitic Diseases (CDIPD), University of California, San Diego (UCSD)**, with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. Drs. McKerrow and Siqueira-Neto will use *in vitro* assays to screen the inhibitors for activity against *T. cruzi*, *T. brucei*, and *Leishmania*.

*Known as EMD in the US and Canada*

FIT2 fellow Dr. Mohammad Shafiul Alam from the **International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)** began his sabbatical with Professors Vicky Avery and Kathy Andrews at the **Griffith Institute for Drug Discovery (GRIDD), Griffith University**, Australia. The sabbatical is supported by funding from IP Australia to WIPO through Funds in Trust (FIT). Through his sabbatical, Dr. Alam will be gaining new skills towards the discovery and development of compounds targeting different *Plasmodium* lifecycle stages. In November, Dr. Alam gave a *seminar* at GRIDD entitled “Current malaria situation in Bangladesh: relevance to new antimalarials.” During his seminar, Dr. Alam discussed about the malaria endemicity, control initiatives, and emergence of artemisinin resistant malaria in Bangladesh.

**New Member Announcement**

We are pleased to announce that the **Centre for Plant Medicine Research** has joined WIPO Re:Search.

**The Centre for Plant Medicine Research**

The Centre for Plant Medicine Research (CPMR) was established by the Government of Ghana in 1975, and is currently based in Mampong-Akuapem. The CPMR has several research departments of relevance to WIPO Re:Search including Microbiology, Phytochemistry, and Clinical Research departments. Research activities ongoing at CPMR include the screening of natural products to identify anti-infectious agents, isolation and identification of active components from medicinal plants, clinical studies of herbal medicines, and the formulation of herbal medicines into proper dosage forms. Among other facilities, CPMR has a herbarium of Ghanaian medicinal plants, and a 750 acre arboretum containing select medicinal plant species.
The WIPO Academy

A key ingredient that enables intellectual property (IP) to be used for innovation and creativity is human knowledge and capacity in the field of IP.

The WIPO Academy is the core entity in WIPO for IP education and training that supports human capacity building, particularly for developing countries, least-developed countries (LDCs), and countries in transition. The Academy works with many partners to facilitate access to IP education and training. From distance learning through professional development training, to post-graduate IP courses, the Academy offers a broad range of learning methods in multiple languages. Courses also cover all aspects of IP from basic to advanced topics, such as the Executive Distance Learning Course on “Promoting Access to Medical Technologies and Innovation,” which explores the intersections between public health, intellectual property, and trade.

Since its establishment in 1998, over half a million people across the world have benefitted from the Academy’s IP education and training courses. Women are among the beneficiaries, representing 51% of all program participants in 2016. The full details of the WIPO Academy’s achievements in 2016 are available in its Annual Review.

Next year will mark the Academy’s 20th Anniversary, and early in the year, the 2018 course catalogue will be published. To find out what is on offer and how you might participate, please visit the WIPO Academy website or take a look at the course catalogue. If you are interested in supporting the Academy’s IP education work, whether it be through scholarship funding, or tutoring and lecturing, please get in touch with us (especially women and those with Arabic, Portuguese, Russian, and Spanish language skills).

Anatole Krattiger
Director, Global Challenges Division, WIPO

Chagas Disease: Current Status and Future Therapeutic Directions

Cathy Manner represented BVGH in San Diego at the Chagas Disease: Current Status and Future Therapeutic Directions symposium, sponsored by Janssen, the Pharmaceutical Companies of Johnson & Johnson (J&J). The event featured several seminars on the Chagas disease research landscape and a roundtable discussion aimed at understanding the gaps and identifying solutions. While in San Diego, Cathy also met with J&J leaders and University of California, San Diego (UCSD) researchers to discuss current WIPO Re:Search collaborations and new partnership opportunities.

UCSD Burroughs-Wellcome Fund Collaborative Research Travel Award

The Burroughs-Wellcome Fund is awarding travel funds to graduate students and post-doctoral scholars from the parasitic worm research community to galvanize collaborations and technology transfer with the University of California, San Diego (UCSD). The Award is open to all research topics relating to the biology and pathology of parasitic roundworms and flatworms. Candidate selection will be based on scientific merit and suitability of the proposed collaboration. Please click here for more information about the award, and apply by submitting the following application to Anna Altman.
**Funding amount:** $2,500 for airfare, accommodation, and incidental expenses of the student or post-doctoral researcher. Sponsoring PIs are eligible for $500 to cover costs of supplies used by the student.

**Funder:** The Burroughs-Wellcome Fund

**Deadline:** January 10, 2018

**Eligibility:** U.S. and foreign graduate students and post-doctoral scholars studying research topics relating to the biology and pathology of parasitic roundworms and flatworms.

For more information about BVGH FundFinder, please email [Cathy Manner](mailto:).
<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
<th>Location</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar. 11 - 16</td>
<td>Gordon Research Conference: Driving Antibacterial Discovery and Development to Address the Clinical Demands of the Next Decade</td>
<td>Ventura, California</td>
<td><a href="#">Website</a></td>
</tr>
<tr>
<td>April 3 - 5</td>
<td>World Vaccine Congress Washington</td>
<td>Washington, D.C.</td>
<td><a href="#">Website</a></td>
</tr>
</tbody>
</table>

*Known as EMD in the US and Canada | **Known as Merck in the US and Canada

Copyright © 2017 BVGH, All rights reserved.

Our mailing address is:
401 Terry Avenue N., Seattle, WA 98109